kabutan

Daito Pharma, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 17%

Fri Apr 10, 2026 3:30 pm JST Earnings

4577 Daito Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

Daito Pharmaceutical Co.,Ltd. <4577> [TSE Prime] announced its financial results after the market closed on April 10th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending May 2026 (June 2025 to February 2026) expanded 2.97 billion yen, an increase 46.3% compared to the same period last year.

In addition, the full-year forecast for consolidated ordinary profit has been revised upward 16.7%, from the previous forecast of 3.00 billion yen to 3.50 billion yen (compared to 2.70 billion yen in the previous period), increasing the growth rate from 10.9% to 29.4%.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated ordinary profit for the December to May period (second half) is expected to increase 40.5%, from the previous forecast of 1.23 billion yen to 1.73 billion yen (compared to 1.23 billion yen in the same period of the previous year), increasing the growth rate from 0.1% to 40.6%.

In the most recent three-month period, from December to February (3Q), the consolidated ordinary profit surged 2.1 times that of the same period last year, reaching 1.21 billion yen. The operating profit margin drastically improved from 3.3% in the same period last year to 9.7%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jun - Feb, 2023 34,662 3,105 3,122 2,339 74.2 79.6 Apr 12, 2024 J-GAAP
Jun - Feb, 2024 36,609 1,869 2,033 1,217 39.9 75.2 Apr 14, 2025 J-GAAP
Jun - Feb, 2025 36,732 2,751 2,974 2,267 76.5 85.0 Apr 10, 2026 J-GAAP
YoY +0.3% +47.2% +46.3% +86.3% +91.9%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec - May, 2025 Prev 27,359 1,373 1,236 1,067 36.9 20 Jan 14, 2026 J-GAAP
Dec - May, 2025 New 25,859 1,673 1,736 1,267 43.8 20 Apr 10, 2026 J-GAAP
Revision Rate -5.5% +21.8% +40.5% +18.7% +18.8%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2026 Prev 52,500 3,000 3,000 2,300 79.4 40 Jul 11, 2025 J-GAAP
May, 2026 New 51,000 3,300 3,500 2,500 86.3 40 Apr 10, 2026 J-GAAP
Revision Rate -2.9% +10.0% +16.7% +8.7% +8.7%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec - May, 2024 26,059 1,148 1,235 1,000 32.9 17.50 Jul 11, 2025 J-GAAP
Dec - May, 2025 Guidance 25,859 1,673 1,736 1,267 43.8 20 Apr 10, 2026 J-GAAP
YoY -0.8% +45.7% +40.6% +26.7% +33.1%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2024 46,895 3,894 3,923 3,295 105.0 30 Jul 12, 2024 J-GAAP
May, 2025 50,643 2,619 2,705 1,908 62.7 35 Jul 11, 2025 J-GAAP
May, 2026 Guidance 51,000 3,300 3,500 2,500 86.3 40 Apr 10, 2026 J-GAAP
YoY +0.7% +26.0% +29.4% +31.0% +37.6%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Dec - Feb, 2024 12,025 398 563 309 10.1 3.3 Apr 14, 2025 J-GAAP
Mar - May, 2025 14,034 750 672 691 22.7 5.3 Jul 11, 2025 J-GAAP
Jun - Aug, 2025 13,011 998 1,052 696 23.2 7.7 Oct 10, 2025 J-GAAP
Sep - Nov, 2025 12,130 629 712 537 18.0 5.2 Jan 14, 2026 J-GAAP
Dec - Feb, 2025 11,591 1,124 1,210 1,034 34.9 9.7 Apr 10, 2026 J-GAAP
YoY -3.6% +182.4% +114.9% +234.6% +245.0%

Related Articles